Interaction of tumor cells with infiltrating lymphocytes via CD70 and CD27 in clear cell renal cell carcinoma

Ruf, Melanie; Moch, Holger; Schraml, Peter

doi:10.1080/2162402x.2015.1049805

Cited by 8 publications

(4 citation statements)

References 8 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the interferon-inducible CXCR3 ligands score based on expression levels of CXCL9 , CXCL10 and CXCL11, is suggested to be linked with different risk subgroups of recurrence and mortality in patients with ccRCC ( 42 ). CD27 + lymphocyte infiltration and the overexpression of CD70 are correlated with poor prognosis in ccRCC, and an elevated serum level of CD27 may be used for anti-CD70 therapy by predicting CD70-expressing ccRCC ( 43 , 44 ). RUNX3 is closely associated with RCC progression, and its high expression can significantly suppress the migration, invasion and angiogenesis in RCC ( 45 - 47 ).…”

Section: Discussionmentioning

confidence: 99%

A 44-gene set constructed for predicting the�prognosis of clear cell renal cell carcinoma

Wang

Liu

2018

Int J Mol Med

View full text Add to dashboard Cite

Clear cell renal cell carcinoma (ccRCC) is the most frequent type of renal cell carcinoma (RCC). The present study aimed to examine prognostic markers and construct a prognostic prediction system for ccRCC. The mRNA sequencing data of ccRCC was downloaded from The Cancer Genome Atlas (TCGA) database, and the GSE40435 dataset was obtained from the Gene Expression Omnibus database. Using the Limma package, the differentially expressed genes (DEGs) in the TCGA dataset and GSE40435 dataset were obtained, respectively, and the overlapped DEGs were selected. Subsequently, Cox regression analysis was applied for screening prognosis-associated genes. Following visualization of the co-expression network using Cytoscape software, the network modules were examined using the GraphWeb tool. Functional annotation for genes in the network was performed using the clusterProfiler package. Finally, a prognostic prediction system was constructed through Bayes discriminant analysis and confirmed with the GSE29609 validation dataset. The results revealed a total of 263 overlapped DEGs and 161 prognosis-associated genes. Following construction of the co-expression network, 16 functional terms and three pathways were obtained for genes in the network. In addition, red, yellow (Involving chemokine ligand 10 (CXCL10), CD27 molecule (CD27) and runt-related transcription factor 3 (RUNX3)], green (Involving angiopoietin-like 4 (ANGPTL4), stannio-calcin 2 (STC2), and sperm associated antigen 4 (SPAG4)], and cyan modules were extracted from the co-expression network. Additionally, the prognostic prediction system involving 44 signature genes, including ANGPTL4, STC2, CXCL10, SPAG4, CD27, matrix metalloproteinase (MMP9) and RUNX3, was identified and confirmed. In conclusion, the 44-gene prognostic prediction system involving ANGPTL4, STC2, CXCL10, SPAG4, CD27, MMP9 and RUNX3 may be utilized for predicting the prognosis of patients with ccRCC.

show abstract

Section: Discussionmentioning

confidence: 99%

A 44-gene set constructed for predicting the�prognosis of clear cell renal cell carcinoma

Wang

Liu

2018

Int J Mol Med

View full text Add to dashboard Cite

show abstract

“… 45 Other studies have shown that Granzyme A (GZMA) is related to the efficacy of ICIs in many cancer types. 46 , 47 TNF-α is an effective inflammatory cytokine mainly produced by activated macrophages, lymphocytes, and other cell types. TNF-α plays an important role in inflammatory immune response.…”

Section: Discussionmentioning

confidence: 99%

GBP5 Expression Predicted Prognosis of Immune Checkpoint Inhibitors in Small Cell Lung Cancer and Correlated with Tumor Immune Microenvironment

Tong,

Li,

Yin

et al. 2023

JIR

View full text Add to dashboard Cite

Background The discovery and development of immune checkpoint inhibitors (ICIs) has significantly enhanced the arsenal of immunotherapy treatments available for cancer patients. The identification of biomarkers that are indicative of an individual’s sensitivity to treatment with ICIs is useful for screening SCLC patients prior to commencement of any ICIs based immunotherapy. However, the relationship between GBP5 and the prognosis of SCLC immunotherapy is still unclear and requires further study. Methods We downloaded two SCLC datasets, namely the George-SCLC and Jiang-SCLC cohorts. We used the TIDE algorithm to predict the efficacy of immunotherapy for SCLC patients. The QuanTIseq, MCPcounter, and EPIC algorithms are used to calculate the proportions of immune cells in SCLC patients. Additionally, we retrospectively collected 35 SCLC samples from the first affiliated hospital of the Hengyang Medical school. Results Patients in each cohort were devided into two groups with high (GBP5-High) and low (GBP5-Low) expression of GBP5. In both cohorts, the GBP5-High population had a higher proportion of patients that responded well to immunotherapy (responders) (p < 0.05). In addition, both GBP5-High subgroups had significantly increased cytotoxicity, chemokines, antigen presenting, and TNF family related genes. We also determined that GBP5 was related to high-level infiltration of B cells, CD4+T cells, CD8+T cells and NK cells. Conclusion In this study, we found that GBP5 has the potential to be used as a biomarker of ICIs efficacy for SCLC patients. GBP5 is related to the quantity of inflammatory molecules, a high level of immune infiltration, and a highly activated immune response pathway.

show abstract

“…The following immunostimulatory antibodies that do not operate as checkpoint blockers are also being evaluated for their safety and efficacy when administered in combination with EBRT: (1) the FDA-approved mAb adalimumab, an inhibitor of TNF and hence of immunosuppressive TAMs, [189][190][191][192][193] which is tested together with EBRT in patients with anaplastic thyroid tumors (NCT02516774); (2) fresolimumab, a mAb that neutralizes TGFb1, 22,66,[194][195][196][197] which is studied in combination with EBRT in individuals with NSCLC (NCT02581787); and (3) varlilumab, an immunostimulatory mAb specific for CD27, [198][199][200][201] which is assessed for its capacity to improve the efficacy of EBRT in subjects with prostate carcinoma (NCT02284971) ( Table 1).…”

Section: E1214790-4mentioning

confidence: 99%

Trial Watch: Immunotherapy plus radiation therapy for oncological indications

et al. 2016

View full text Add to dashboard Cite

Malignant cells succumbing to some forms of radiation therapy are particularly immunogenic and hence can initiate a therapeutically relevant adaptive immune response. This reflects the intrinsic antigenicity of malignant cells (which often synthesize a high number of potentially reactive neo-antigens) coupled with the ability of radiation therapy to boost the adjuvanticity of cell death as it stimulates the release of endogenous adjuvants from dying cells. Thus, radiation therapy has been intensively investigated for its capacity to improve the therapeutic profile of several anticancer immunotherapies, including (but not limited to) checkpoint blockers, anticancer vaccines, oncolytic viruses, Toll-like receptor (TLR) agonists, cytokines, and several small molecules with immunostimulatory effects. Here, we summarize recent preclinical and clinical advances in this field of investigation.

show abstract

Interaction of tumor cells with infiltrating lymphocytes via CD70 and CD27 in clear cell renal cell carcinoma

Cited by 8 publications

References 8 publications

A 44-gene set constructed for predicting the�prognosis of clear cell renal cell carcinoma

A 44-gene set constructed for predicting the�prognosis of clear cell renal cell carcinoma

GBP5 Expression Predicted Prognosis of Immune Checkpoint Inhibitors in Small Cell Lung Cancer and Correlated with Tumor Immune Microenvironment

Trial Watch: Immunotherapy plus radiation therapy for oncological indications

Contact Info

Product

Resources

About